(Total Views: 806)
Posted On: 08/27/2025 10:19:44 AM
Post# of 158141
100% it's Keytruda..Re-read & Re-listen:
___
Re-read Tecentriq:
Triple-negative breast cancer (TNBC): Withdrawn in August 2021, after a confirmatory study showed that Tecentriq combined with chemotherapy did not improve survival.
Urothelial carcinoma (bladder cancer): Withdrawn in March 2021 for previously treated metastatic bladder cancer and again in November 2022 for first-line treatment.
* These were failed Accelerated Approvals
Our mTNBC ICI combos were Keytruda & Tecentriq.
5 years ago.
___
Re-listen to Dr. J video on our new acceptance programs:
Compassionate Use:
TNBC
eIND's:
Prostate. Pancreatic. Sarcoma &..... Ureothelial cancers -- ( kidney & bladder )
We are only giving Roche a chance to reel in some success...
While Keytruda will be the direct involvement with Leronlimab.
Keytruda -- the top selling drug worldwide & well marketed.
BOOOM !!!
___
Re-read Tecentriq:
Triple-negative breast cancer (TNBC): Withdrawn in August 2021, after a confirmatory study showed that Tecentriq combined with chemotherapy did not improve survival.
Urothelial carcinoma (bladder cancer): Withdrawn in March 2021 for previously treated metastatic bladder cancer and again in November 2022 for first-line treatment.
* These were failed Accelerated Approvals
Our mTNBC ICI combos were Keytruda & Tecentriq.
5 years ago.
___
Re-listen to Dr. J video on our new acceptance programs:
Compassionate Use:
TNBC
eIND's:
Prostate. Pancreatic. Sarcoma &..... Ureothelial cancers -- ( kidney & bladder )
We are only giving Roche a chance to reel in some success...
While Keytruda will be the direct involvement with Leronlimab.
Keytruda -- the top selling drug worldwide & well marketed.
BOOOM !!!
(9)
(0)
